Daraxonrasib is going up against standard-of-care chemotherapy, in the second line for metastatic pancreatic cancer (and its being tested as first-line therapy, and in resectable disease, alongside this)
Cagrilintide monotherapy for treatment of obesity In a 26-week phase 2 trial (n=706, 62 Percentage women, mean age 52 years), cagrilintide was evaluated in 5 groups of subjects receiving 0.3, 0.6, 1.2, 2.4, and 4.5 mg/week as treatment for obesity in comparison with liraglutide 3.0 mg/day, and placebo (table 1) [9]
32 MoritaR.NakaneS.ShimadaA.InoueM.IinoH.WakamatsuT.et al (2010)
2011 Jan
Stroke survivors took a mean of 693 224 steps during the VR game, reached 66.4% 10.7 of predicted maximum heart rate, and spent 25.5 13.5 minutes using the game